Patient access to rheumatoid arthritis treatments

European Journal of Health Economics

Volumn 8, Issue SUPPL. 8, 2008, Pages

  Jönsson, Bengt ^a  

^a STOCKHOLM SCHOOL OF ECONOMICS   (Sweden)

Author keywords

Rheumatoid arthritis; Treatment access

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ARTICLE; DRUG COST; HEALTH CARE ACCESS; HEALTH CARE SYSTEM; HEALTH INSURANCE; HUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DISEASE PROGRESSION; DRUG COSTS; EUROPE; HEALTH SERVICES ACCESSIBILITY; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; NORTH AMERICA; RECEPTORS, TUMOR NECROSIS FACTOR; SWEDEN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 38449085323     PISSN: 16187598     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10198-007-0086-x     Document Type: Article

References (34)

1. Silman, A., Hochberg, M.: Epidemiology of rheumatic diseases. Oxford University Press, Oxford (1993)
2. Allaire, S.H., Prashker, M.J., Meenan, R.F.: The costs of rheumatoid arthritis. Pharmacoeconomics 6, 513-522 (1994)
3. Meenan, R.F., Yelin, E.H., Nevitt, M., Epstein, W.V.: The impact of chronic disease: a sociomedical profile of rheumatoid arthritis. Arthritis Rheum 24, 544-549 (1981)
4. Pincus, T.: The underestimated long-term medical and economic consequences of rheumatoid arthritis. Drugs 50(Suppl 1), 1-14 (1995)
5. Young, A., Wilkinson, P., Talamo, J., et al.: Socioeconomic deprivation and rheumatoid disease. What lessons for the health service? Ann Rheum Dis 59, 794-799 (2000)
6. Cooper, N.J.: Economic burden of rheumatoid arthritis: a systematic review. Rheumatology (Oxford) 39, 28-33 (2000)
7. Gabriel, S.E., Crowson, C.S., Luthra, H.S., et al.: Modeling the lifetime costs of rheumatoid arthritis. J Rheumatol 26, 1269-1274 (1999)
8. Jonsson, D., Husberg, M.: Socioeconomic costs of rheumatic diseases. Implications for technology assessment. Int J Technol Assess Health Care 16, 1193-1200 (2000)
9. Kobelt, G., Eberhardt, K., Jonsson, L., Jonsson, B.: Economic consequences of the progression of rheumatoid arthritis in Sweden. Arthritis Rheum 42, 347-356 (1999)
10. Kobelt, G., Jönsson, L., Fredrikson, S.A.: New disease model to estimate the cost of disease progression for different types of MS, different subgroups of patients. Eur J Health Econ 4, 50-59 (2003)
11. Katz, P.P.: The impact of rheumatoid arthritis on life activities. Arthritis Care Res 8, 272-278 (1995)
12. Pincus, T., Callahan, L.F., Sale, W.G., et al.: Severe functional declines, work disability, and increased mortality in 75 rheumatoid arthritis patients studied over 9 years. Arthritis Rheum 27, 864-872 (1984)
13. Young, A., Dixey, J., Kulinskaya, E., et al.: Which patients stop working because of rheumatoid arthritis? Results of 5 years' follow up in 732 patients from the Early RA Study (ERAS). Ann Rheum Dis 61, 335-340 (2002)
14. Fex, E., Larsson, B-M., Nived, K., Eberhardt, K.: Impact of rheumatoid arthritis on work status and social and leisure time activities in patients followed 8 years from onset. J Rheumatol 25, 44-50 (1997)
15. Stone, C.E.: The lifetime economic costs of rheumatoid arthritis. J Rheumatol 11, 819-827 (1984)
16. Kobelt, G., Jonsson, L., Lindgren, P., et al.: Modeling the progression of rheumatoid arthritis: a two-country model to estimate costs and consequences of rheumatoid arthritis. Arthritis Rheum 46, 2310-2319 (2002)
17. McIntosh, E.: The cost of rheumatoid arthritis. Br J Rheumatol 35, 781-790 (1996)
18. Kobelt, G.: Health economic issues in rheumatoid arthritis. Scand J Rheumatol 35, 415-425 (2006)
19. Wong, J., Singh, G., Kavanough, A.: Estimating the cost-effectiveness of infliximab for rheumatoid arthritis. Am J Med 113, 400-408 (2002)
20. Kobelt, G., Eberhardt, K., Geborek, P.: TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in southern Sweden. Ann Rheum Dis 63, 4-10 (2004)
21. Kobelt, G., Jonsson, L., Young, A., Eberhardt, K.: The cost-effectiveness of infliximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study. Rheumatology (Oxford) 42(2), 326-335 (2003)
22. Kobelt, G., Lindgren, P., Lindroth, Y., et al.: Modelling the effect of function and disease activity on costs and quality of life in rheumatoid arthritis. Rheumatology (Oxford) 44, 1169-1175 (2005)
23. Kobelt, G., Lindgren, P., Singh, A., Klareskog, L.: Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial. Ann Rheum Dis 64, 1174-1179 (2005)
24. Kobelt, G., Lindgren, P., Young, A.: Modelling the costs and effects of leflunomide in rheumatoid arthritis. Eur J Health Econ 3, 180-187 (2002)
25. Brennan, A., Bansback, N., Reynolds, A., Conway, P.: Modeling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK. Rheumatology 43, 62-72 (2004)
26. Bansback, N.J., Brennan, A., Ghatnekar, O.: Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden. Ann Rheum Dis 64, 995-1002 (2005)
27. Barbieri, M., Wong, J.B., Drummond, M.: The cost-effectiveness of infliximab for severe treatment-resistant rheumatoid arthritis in the UK. Pharmacoeconomics 23, 607-618 (2005)
28. Coyle, D., Judd, M., Blumenauer, B., et al.: Infliximab and etanercept in patients with rheumatoid arthritis: a systematic review and economic evaluation. Ottawa; Report no 64 (2006)
29. Brennan, A., Bansback, N., Nixon, R., et al.: Modelling the cost effectiveness of TNF-{alpha} antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry. Rheumatology (Oxford) (2007)
30. Cochrane, A.: Effectiveness and efficiency: random reflections on health services. Cambridge University Press, Cambridge (1971)
31. Wennberg, J.: On the appropriateness of small-area analysis for cost-containment. Health Aff 15, 164-167 (1996)
32. Aletaha D., Smolen J.S.: DMARD use in early rheumatoid arthritis. Lessons from observations in patients with established disease. Clin Exp Rheumatol 21(Suppl 31), S169-S173 (2003)
33. Smolen, J.S., Aletaha, D.: Patients with rheumatoid arthritis in clinical care. Ann Rheum Dis 63, 221-225 (2004)
34. Aletaha, D., Smolen, J.S.: The definition and measurement of disease modification in inflammatory rheumatic diseases. Rheum Dis Clin North Am 32, 9-44vii (2006)